
Conference Coverage
Trending on the Eye Care Network
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
AAO 2026: BRUNELLO 1-year results for remigromig in DME
Slowing Stargardt: What a 36% reduction in lesion growth could mean for adolescent patients
AAO 2026: Blood pressure and optic nerve perfusion: a complex relationship
Latest News

Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026

EURETINA 2026: Duravyu misses LUGANO endpoint but cuts treatment burden by 42%

EURETINA 2026: Real-world evidence on retinal biosimilars

EURETINA 2026: Retinal laser myths and simulation: a Q&A with Serena Salvatore, MD

EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Three studies use OCT and OCTA to track AMD treatment response, flag diabetic retinopathy before oedema and confirm ocular toxoplasmosis.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Alessandro Arrigo, MD, describes an early-stage method that uses blue light autofluorescence imaging to grade cataracts objectively. He explains why a reproducible score could help with surgeon selection, IOL power calculation, and retinal image quantification.

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.

NESTS survey reveals patients often normalize dry eye symptoms, delaying care despite major impacts on daily life.

The 26th EURETINA Congress convenes in Vienna, Austria, from October 1–4, headlined by a new World Retina networking initiative and a revamped Free Paper Forum stage.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

Bausch + Lomb's SeeLyra femtosecond laser platform, featuring live OCT imaging, has received CE mark approval for cataract, LASIK, and corneal procedures in Europe.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.




























